RNA therapies get another 2020 win with inclisiran approval

The migration of new modalities into prevalent indications took another step forward on Friday with the European Commission’s approval of Novartis’ siRNA therapy Leqvio inclisiran to treat hypercholesterolemia or mixed dyslipidemia.

The therapy, which targets PCSK9, could solve the adherence issues of other cholesterol lowering drugs with subcutaneous dosing twice a year after an initial dose and one at three months. Statins require daily oral dosing and mAbs against PCSK9 involve infusions every two weeks or monthly...